Research programme: natural killer cell therapy - CellProtect Nordic Pharmaceuticals

Drug Profile

Research programme: natural killer cell therapy - CellProtect Nordic Pharmaceuticals

Alternative Names: CellProtect

Latest Information Update: 21 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Avaris
  • Developer Avaris; CellProtect Nordic Pharmaceuticals
  • Class Natural killer cell therapies
  • Mechanism of Action Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Multiple myeloma
  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 21 Dec 2017 Cellprotect Nordic Pharmaceuticals has patents pending for natural killer cell therapy in USA, China, EU (https://www.google.co.in/patents/EP2411507A1)
  • 15 Dec 2017 Phase-I/II clinical trials in Multiple myeloma (Adjunctive treatment) in Sweden (IV), before December 2017
  • 15 Dec 2017 Research programme: natural killer cell therapy - CellProtect Nordic Pharmaceuticals receives Orphan Drug status for Multiple myeloma (Adjunctive treatment) in European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top